IFP Advisors’s Theriva Biologics TOVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3 | Hold |
11
| – | – | ﹤0.01% | 5114 |
|
|
2026
Q1 | $2 | Hold |
11
| – | – | ﹤0.01% | 5007 |
|
|
2025
Q4 | $2 | Hold |
11
| – | – | ﹤0.01% | 4874 |
|
|
2025
Q3 | $4 | Hold |
11
| – | – | ﹤0.01% | 4813 |
|
|
2025
Q2 | $5 | Hold |
11
| – | – | ﹤0.01% | 4887 |
|
|
2025
Q1 | $12 | Hold |
11
| – | – | ﹤0.01% | 4219 |
|
|
2024
Q4 | $19 | Sell |
11
-296
| -96% | -$433 | ﹤0.01% | 4469 |
|
|
2024
Q3 | $58 | Buy |
307
+295
| +2,458% | +$1.44K | ﹤0.01% | 3252 |
|
|
2024
Q2 | $70 | Hold |
12
| – | – | ﹤0.01% | 3176 |
|
|
2024
Q1 | $139 | Hold |
12
| – | – | ﹤0.01% | 3046 |
|
|
2023
Q4 | $127 | Sell |
12
-3
| -20% | -$37 | ﹤0.01% | 2961 |
|
|
2023
Q3 | $206 | Hold |
15
| – | – | ﹤0.01% | 3190 |
|
|
2023
Q2 | $382 | Hold |
15
| – | – | ﹤0.01% | 3235 |
|
|
2023
Q1 | $572 | Hold |
15
| – | – | ﹤0.01% | 3170 |
|
|
2022
Q4 | $2K | Sell |
15
-138
| -90% | -$2.51K | ﹤0.01% | 4228 |
|
|
2022
Q3 | $13K | Buy |
153
+138
| +920% | +$5.3K | ﹤0.01% | 3478 |
|
|
2022
Q2 | $13K | Hold |
15
| – | – | ﹤0.01% | 3220 |
|
|
2022
Q1 | $13K | Sell |
15
-40
| -73% | -$2.73K | ﹤0.01% | 3220 |
|
|
2021
Q4 | $5K | Buy |
55
+40
| +267% | +$3.77K | ﹤0.01% | 2515 |
|
|
2021
Q3 | $3K | Hold |
15
| – | – | ﹤0.01% | 2759 |
|
|
2021
Q2 | $2K | Hold |
15
| – | – | ﹤0.01% | 2785 |
|
|
2021
Q1 | $3K | Hold |
15
| – | – | ﹤0.01% | 2593 |
|
|
2020
Q4 | $1K | Hold |
15
| – | – | ﹤0.01% | 2826 |
|
|
2020
Q3 | $2K | Hold |
15
| – | – | ﹤0.01% | 2517 |
|
|
2020
Q2 | $2K | Hold |
15
| – | – | ﹤0.01% | 2431 |
|
|
2020
Q1 | $1K | Hold |
15
| – | – | ﹤0.01% | 2618 |
|
|
2019
Q4 | $2K | Hold |
15
| – | – | ﹤0.01% | 2556 |
|
|
2019
Q3 | $2K | Buy |
+15
| New | +$1.81K | ﹤0.01% | 2735 |
|
|
2019
Q1 | – | Sell |
-15
| Closed | -$2K | – | 3359 |
|
|
2018
Q4 | $2K | Sell |
15
-4
| -21% | -$950 | ﹤0.01% | 3197 |
|
|
2018
Q3 | $12K | Hold |
19
| – | – | ﹤0.01% | 2760 |
|
|
2018
Q2 | $39K | Hold |
19
| – | – | ﹤0.01% | 2073 |
|
|
2018
Q1 | $83K | Hold |
19
| – | – | ﹤0.01% | 1499 |
|
|
2017
Q4 | $83K | Hold |
19
| – | – | ﹤0.01% | 1511 |
|
|
2017
Q3 | $153K | Hold |
19
| – | – | 0.01% | 1309 |
|
|
2017
Q2 | $93K | Hold |
19
| – | – | ﹤0.01% | 1566 |
|
|
2017
Q1 | $103K | Hold |
19
| – | – | ﹤0.01% | 1482 |
|
|
2016
Q4 | $125K | Hold |
19
| – | – | 0.01% | 1313 |
|
|
2016
Q3 | $282K | Hold |
19
| – | – | 0.01% | 840 |
|
|
2016
Q2 | $295K | Buy |
+19
| New | +$358K | 0.02% | 799 |
|
|
2016
Q1 | – | Sell |
-15
| Closed | -$298K | – | 3364 |
|
|
2015
Q4 | $298K | Buy |
+15
| New | +$317K | 0.02% | 668 |
|
Other funds holding TOVX
IC
VF
XT
IFP Advisors's TOVX Position: Q2 2026 in Review
IFP Advisors held its Theriva Biologics (TOVX) position steady in Q2 2026 at 11 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #5114.
IFP Advisors first reported a position in TOVX in Q4 2015 and has held it in 40 quarters since. The position peaked at $298K in Q4 2015. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.
- IFP Advisors held 11 shares of Theriva Biologics worth $3 as of Q2 2026.
- IFP Advisors left its Theriva Biologics share count unchanged in Q2 2026.
- Theriva Biologics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #5114 holding.
- IFP Advisors first reported a position in Theriva Biologics in Q4 2015 and has held it in 40 quarters since.
- IFP Advisors's Theriva Biologics position peaked at $298K in Q4 2015.
- 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.